NEIL HOWARD GOLDSTEIN, MD

Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.

None Reported

None Reported

Safety and Immunogenicity of Heterologous and Homologous Two Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study
Journal of Infectious Diseases
Date: 09 2020
doi.org/10.1093/infdis/jiaa586

Safety and Immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN®-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): randomized, observer-blind, participant-blind, placebo controlled, phase 2 trial
Lancet Infectious DIseases
Date: 11 2020
doi.org/10.1016/S1473-3099(20)30476-X

. Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial
Lancet Infectious DIseases
Date: 09 2021
DOI: 10.1016/S1473-3099(21)00125-0

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial
Lancet Infectious DIseases
Date: 09 2021
DOI: 10.1016/S1473-3099(21)00128-6

Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
Npj Vaccines
Date: 12 2021
doi.org/10.1038/s41541-021-00402-8

First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study
PLoS One
Date: 10 2022
doi.org/10.1371/journal.pone.0274906